一般演題3-15D AML：新規治療

[OS3-15D-1] Venetoclax combined with azacitidine for Japanese patients with relapsed/refractory AML

Noriko Fukuhara¹, Ilseung Choi², Kensuke Usuki³, Takahiro Yamauchi⁴, Jalaja Potluri⁵, Paulo Maciag⁵, Wan-Jen Hong⁶, Hideyuki Honda⁷, Ahmed Salem⁵, Shuichi Taniguchi⁸ (1.Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan, 2.Department of Hematology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Fukuoka, Japan, 3.Department of Hematology, NTT Medical Center Tokyo, Tokyo, Tokyo, Japan, 4.Department of Hematology and Oncology, University of Fukui Hospital, Fukui, Fukui, Japan, 5.AbbVie, Inc., North Chicago, IL, United States of America, 6.Genentech, Inc., South San Francisco, CA, United States of America, 7.AbbVie GK, Tokyo, Tokyo, Japan, 8.Department of Hematology, Toranomon Hospital, Tokyo, Tokyo, Japan)